FDA
approval
· 2025-10-28
FDA Approved: TRIUMEQ — Supplemental Application (ViiV Healthcare Company)
Summary
The FDA approved a supplemental application for TRIUMEQ, a fixed-dose combination antiretroviral therapy consisting of abacavir sulfate, dolutegravir sodium, an…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for TRIUMEQ (ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE)